AR012702A1 - COMBINATION OF (-) - (1S, 4R) -4- [2-AMINO-6- (CICLOPROPILAMINO) -9H-PURIN-9-IL] - 2-CYCLOPENTENO-1-METHANOL AND A REVERSE NON-NUCLEOSIDUNE FORMULATION TRANSCRIPTASE INHIBITOR PHARMACEUTICAL WHICH INCLUDES THE COMBINATION, ITS MEDICAL USE IN THERAPY TO TREAT HIV INFECTION, AND A PACKAGING FOR THE PATIENT - Google Patents

COMBINATION OF (-) - (1S, 4R) -4- [2-AMINO-6- (CICLOPROPILAMINO) -9H-PURIN-9-IL] - 2-CYCLOPENTENO-1-METHANOL AND A REVERSE NON-NUCLEOSIDUNE FORMULATION TRANSCRIPTASE INHIBITOR PHARMACEUTICAL WHICH INCLUDES THE COMBINATION, ITS MEDICAL USE IN THERAPY TO TREAT HIV INFECTION, AND A PACKAGING FOR THE PATIENT

Info

Publication number
AR012702A1
AR012702A1 ARP980102250A ARP980102250A AR012702A1 AR 012702 A1 AR012702 A1 AR 012702A1 AR P980102250 A ARP980102250 A AR P980102250A AR P980102250 A ARP980102250 A AR P980102250A AR 012702 A1 AR012702 A1 AR 012702A1
Authority
AR
Argentina
Prior art keywords
combination
purin
methanol
amino
patient
Prior art date
Application number
ARP980102250A
Other languages
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709945.1A external-priority patent/GB9709945D0/en
Priority claimed from GBGB9719883.2A external-priority patent/GB9719883D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR012702A1 publication Critical patent/AR012702A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen combinaciones terapéuticas de (-)(1S,4R)-4-[2-amino-6- (ciclopropilamino)-9H-purin-9-il]-2-ciclopenteno-1-metanol (1592U89) einhibidores de transcriptasa reversa, no nucleosidos que tienen actividad anti- VIH. La presente invencion también está relacionada con composicionesfarmacéuticas que contienen las combinaciones, su uso en el tratamiento de infecciones VIH y un empaque para el paciente que contiene dichas combinacionesTherapeutic combinations of (-) (1S, 4R) -4- [2-amino-6- (cyclopropylamino) -9H-purin-9-yl] -2-cyclopentene-1-methanol (1592U89) and reverse transcriptase inhibitors are described , non-nucleosides that have anti-HIV activity. The present invention is also related to pharmaceutical compositions containing the combinations, their use in the treatment of HIV infections and a patient package containing such combinations.

ARP980102250A 1997-05-17 1998-05-14 COMBINATION OF (-) - (1S, 4R) -4- [2-AMINO-6- (CICLOPROPILAMINO) -9H-PURIN-9-IL] - 2-CYCLOPENTENO-1-METHANOL AND A REVERSE NON-NUCLEOSIDUNE FORMULATION TRANSCRIPTASE INHIBITOR PHARMACEUTICAL WHICH INCLUDES THE COMBINATION, ITS MEDICAL USE IN THERAPY TO TREAT HIV INFECTION, AND A PACKAGING FOR THE PATIENT AR012702A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9709945.1A GB9709945D0 (en) 1997-05-17 1997-05-17 A novel salt
GBGB9719883.2A GB9719883D0 (en) 1997-09-19 1997-09-19 Antiviral combinations

Publications (1)

Publication Number Publication Date
AR012702A1 true AR012702A1 (en) 2000-11-08

Family

ID=26311543

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102250A AR012702A1 (en) 1997-05-17 1998-05-14 COMBINATION OF (-) - (1S, 4R) -4- [2-AMINO-6- (CICLOPROPILAMINO) -9H-PURIN-9-IL] - 2-CYCLOPENTENO-1-METHANOL AND A REVERSE NON-NUCLEOSIDUNE FORMULATION TRANSCRIPTASE INHIBITOR PHARMACEUTICAL WHICH INCLUDES THE COMBINATION, ITS MEDICAL USE IN THERAPY TO TREAT HIV INFECTION, AND A PACKAGING FOR THE PATIENT

Country Status (12)

Country Link
EP (1) EP0979082A1 (en)
JP (1) JP2001525839A (en)
AR (1) AR012702A1 (en)
AU (1) AU7912398A (en)
BR (1) BR9809127A (en)
CA (1) CA2289655A1 (en)
CO (1) CO4950569A1 (en)
HR (1) HRP980264A2 (en)
MA (1) MA26496A1 (en)
NO (1) NO995620L (en)
PE (1) PE74799A1 (en)
WO (1) WO1998052570A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990030A2 (en) * 1998-02-17 1999-10-31 Michael B. Maurin Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
CO5070643A1 (en) * 1998-05-27 2001-08-28 Merck & Co Inc FORMULATION IN COMPRESSED TABLETS
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
WO2013111147A1 (en) * 2011-12-19 2013-08-01 Hetero Research Foundation Extended release compositions of nevirapine
WO2014133085A1 (en) * 2013-02-27 2014-09-04 国立大学法人京都大学 Pharmaceutical composition for prevention and/or treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc

Also Published As

Publication number Publication date
HRP980264A2 (en) 1999-02-28
WO1998052570A1 (en) 1998-11-26
JP2001525839A (en) 2001-12-11
CA2289655A1 (en) 1998-11-26
PE74799A1 (en) 1999-08-13
MA26496A1 (en) 2004-12-20
NO995620L (en) 2000-01-14
CO4950569A1 (en) 2000-09-01
BR9809127A (en) 2000-08-01
AU7912398A (en) 1998-12-11
EP0979082A1 (en) 2000-02-16
NO995620D0 (en) 1999-11-16

Similar Documents

Publication Publication Date Title
AR020055A1 (en) A PHARMACEUTICAL OR COSMETIC COMPOSITION CONTAINING A SUBSTANCE OF ACTIVE ENAMEL, USES OF SUCH COMPOSITION AND A METHOD TO PREPARE THE SAME.
PT88985A (en) Process for the preparation of nasal and ophthalmic pharmaceutical compositions containing azelastine
ES2145913T3 (en) METALOPROTEASE INHIBITORS.
HUP0104718A2 (en) Micronized eplerenone compositions and process for their preparation
BR9406893A (en) Use of ninth- and decapeptides for the preparation of a medicine to fight AIDS
RU94026283A (en) Pharmaceutical compound
RU2007104774A (en) COMBINATION OF ANTI-HIV REVERSE TRANSCRIPTASE AND PROTEASES INHIBITORS
AR012294A1 (en) DERIVATIVES OF SULFONAMIDE, A PROCEDURE FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A MEDICINAL PRODUCT.
PT914110E (en) METHOD OF MODULATING MICRO-CIRCULATION
AR031117A1 (en) USE OF LIPASE INHIBITORS AND BILIAR ACID SEQUENCERS FOR THE PREPARATION OF A MEDICINAL PRODUCT, SUCH LIPASE INHIBITOR AND BILIAR ACID SEQUENCER AND PHARMACEUTICAL COMBINATION
DE69718734T2 (en) Bicyclic aromatic compounds
HUP0001632A2 (en) Pharmaceutical compositions comprising selective phosphodiestherase inhibitors
HUP0100539A2 (en) Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use
IT1170214B (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PERIPHERAL ARTERIOPATHIES
AR012702A1 (en) COMBINATION OF (-) - (1S, 4R) -4- [2-AMINO-6- (CICLOPROPILAMINO) -9H-PURIN-9-IL] - 2-CYCLOPENTENO-1-METHANOL AND A REVERSE NON-NUCLEOSIDUNE FORMULATION TRANSCRIPTASE INHIBITOR PHARMACEUTICAL WHICH INCLUDES THE COMBINATION, ITS MEDICAL USE IN THERAPY TO TREAT HIV INFECTION, AND A PACKAGING FOR THE PATIENT
MXPA03010679A (en) Compositions for promoting healing of bone fracture.
ATE395064T1 (en) COMBINATION PREPARATIONS OF 3-N-FORMYLHYDROXYLAMINOPROPYLPHOSPHONY ACID DERIVATIVES OR 3-N-ACETYLHYDROXYLAMINOPROPYLPHOSPHONY ACID DERIVATIVES WITH SPECIAL PHARMACEUTICAL ACTIVE INGREDIENTS
BR0206954A (en) Cancer Therapy Process
ITMI932189A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING N-ACETYL CARNOSINE FOR THE TREATMENT OF CATARACT
MX9306607A (en) TILIDINE DINDIHYDROGEN-OTORPHOSPHATE, PROCEDURE FOR ITS OBTAINING AND THE PHARMACEUTICAL PREPARATIONS THAT CONTAIN IT.
UY26595A1 (en) LOW DOSE USE USE FORMULATIONS
RU2005131578A (en) APLIDINE FOR TREATMENT OF MULTIPLE MYELOMA
AR002957A1 (en) A COMBINATION OF USEFUL COMPOUNDS, THEIR USE TO PREPARE A MEDICINAL PRODUCT, AND A PHARMACEUTICAL COMPOSITION AND COMBINATION THAT CONTAIN THEM.
BR9907234A (en) Fat-binding polymers
BR9809124A (en) Combination, formulation, pharmaceutical, process for the treatment of an HIV infection in an infected animal, use of (-) - (1s, 4r) -4- [2-amino-6- (cyclopropylamino) -9h-purin- 9-yl) -2-cyclopentene-1-methanol, and, patient package